Global Clinical-Trial Capability / 全球临床试验能力

Definition

Global clinical-trial capability is the organizational capacity to design, fund, operate, interpret, and regulate studies across populations, hospitals, legal systems, ethical regimes, and approval markets.

Current Synthesis

China’s large patient base and concentration in major hospitals can accelerate recruitment and lower some trial costs, but domestic efficiency is not the same as global evidence portability. Population composition, mutation patterns, disease causes, standards of care, ethics, law, hospital practice, and regulator expectations can differ. Firms therefore choose between licensing foreign rights to an experienced partner and building the costly local teams and tacit knowledge required for self-globalization.

Key Claims

• Dense patient access can make recruitment faster without guaranteeing that results generalize internationally.
• Multinational trials test both a therapy and the sponsor’s ability to coordinate different clinical, legal, ethical, and regulatory systems.
• Local tacit knowledge and experienced teams cannot be replaced fully by short visits or central instructions.
• Licensing can transfer global-development risk to a larger partner, while self-development retains more control and demands more capital and infrastructure.
• Independent global execution is a company-capability signal, not by itself proof that a medicine is effective.

Evidence

• Domestic efficiency - EP294 一款救命药，要等多少年：中国创新药的崛起之路 attributes faster recruitment partly to many patients being concentrated in large Chinese hospitals.
• Transferability boundary - EP294 一款救命药，要等多少年：中国创新药的崛起之路 notes that mutation patterns and disease causes may vary with population and lifestyle, limiting automatic overseas application.
• Operating burden - EP294 一款救命药，要等多少年：中国创新药的崛起之路 describes high multinational-trial costs and the need for teams familiar with local approval, law, ethics, and hospital systems.
• Partner-or-build choice - EP294 一款救命药，要等多少年：中国创新药的崛起之路 contrasts overseas-rights licensing with independently funded global trials and commercialization.

Counterevidence & Qualifications

The source gives speaker-reported cost ranges and generalized population comparisons without protocols or datasets. Concentrated recruitment may also create dependence on a small number of experts. Global trials can improve breadth yet still fail because of design, biology, execution, or commercial conditions.

What Changed

• Established the difference between domestic recruitment efficiency, evidence transferability, and full multinational operating capability.

Related Concepts

• China Biotech Globalization - strategic route through licensing, co-development, or self-globalization.
• Global Pharma Commercialization - broader capability that begins after or alongside global development.
• Clinical Data Trust Rebuilding - credibility condition for cross-border reliance on trial results.
• Innovation-Drug Translation System / 创新药转化系统 - wider system in which multinational trials are one gate.
• Biotech License-Out Arbitrage - transaction route that can transfer overseas development responsibility.